Abstract:Christopher L Robinson, 1, &ast Alexandra CG Fonseca, 2, &ast Efemena M Diejomaoh, 3, &ast Ryan S D'Souza, 4 Michael E Schatman, 5, 6, &ast Vwaire Orhurhu, 7, 8, &ast Trent Emerick 9, &ast 1 Beth Israel Deaconess Medical Center, Department of Anesthesiology, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA; 2 Department of Anesthesiology, Perioperative & Pain Medicine, Harvard Medical School, Brigham & Women's Hospital, Boston, MA, USA; 3 Department of Psychiatry & Behavioral Science, Meharry Medical College, Nashville, TN, USA; 4 Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Rochester, Rochester, MN, USA; 5 Department of Anesthesiology, Perioperative Care, and Pain Medicine, NYU Grossman School of Medicine, New York, NY, USA; 6 Department of Population Health-Division of Medical Ethics, NYU Grossman School of Medicine, New York, NY, USA; 7 University of Pittsburgh Medical Center, Susquehanna, Williamsport, PA, USA; 8 MVM Health, East Stroudsburg, PA, USA; 9 University of Pittsburgh Medical Center, Department of Anesthesiology and Perioperative Medicine, Chronic Pain Division, Pittsburgh, PA, USA &astThese authors contributed equally to this work Correspondence: Vwaire Orhurhu, University of Pittsburgh Medical Center, Susquehanna, Williamsport, PA, USA, Email Introduction: Amid a lack of effective chronic pain treatments, psychedelics have gained attention as a potential solution, although their Schedule 1 classification poses challenges. Psychedelics, such as lysergic acid diethylamide (LSD) and psilocybin, have gained popularity as alternatives and adjuncts for chronic pain treatment. Studies suggest that they may modulate pain processing through agonism primarily at the serotonin receptor, 5-HT 2A . One of the first of its nature, we present an artificial intelligence (AI)-powered scoping review primarily focusing on evaluating psychedelics for chronic pain conditions such as cluster headache, phantom limb pain, and fibromyalgia. Methods: In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, we used an AI-powered comprehensive search strategy utilizing the ChatGPT4.0 Bing chat to search Medline, Embase, Cochrane, and Google Scholar for articles addressing chronic pain. The query was performed on June 1, 2023, focusing on psychedelics for chronic, non-cancer pain including headache disorders. Inclusion criteria were English-only, peer-reviewed articles involving human participants > 18 years, focusing on chronic pain conditions (eg, phantom limb pain and cluster headache), using LSD, 2.5-dimethoxy-4-bromophenethylamine (2C-B), N, N-dimethyltryptamine (DMT), psilocybin, or mescaline. Exclusion criteria were reviews, editorials, and opinion articles and studies focusing on tetrahydrocannabinol/cannabis and/or ketamine. Results: A total of 186 unique database entries were retrieved, of which nine studies were included in the scoping review. These included four case reports/series, an open-label study, a cohort study, two online surveys, and a randomized, double-blind, placebo-controlled trial. They comprised three studies addressing phantom limb pain, four addressing cluster headaches, and two addressing fibromyalgia, spinal cord injury, complex regional pain syndrome, and lumbar radiculopathy. Conclusion: Psychedelics may have potential in alleviating pain symptoms secondary to a multitude of chronic pain conditions. However, further randomized, double-blind, placebo-controlled trials are needed to further explore and evaluate the role of psychedelics in chronic, non-cancer pain. Keywords: psilocybin, mescaline, lysergic acid diethylamide, headache, phantom limb pain, scoping review Chronic pain, defined as pain that persists for >3 months or reoccurs, is one of the leading causes of disability in the United States, affecting between 50 and 100 million people and costing annually nearly $600 billion in healthcare bills and lost economic activity alone. 1–3 Moreover, with what initially appeared to be a solution to chronic pain in the 1990s, the prescription opioid epidemic wreaked havoc on the lives of those who were affected and reportedly killed many in the United States, although there are no reliable data that allow for accurate assessment of the death toll. Furthermore, the economic cost alone attributable to the opioid epidemic was estimated at $1.5 trillion, although there are no reliable data indicatin -Abstract Truncated-

Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain

Psilocybin as a novel treatment for chronic pain

A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

The Analgesic Effects of (5R,6R)6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1] Octane on a Mouse Model of Neuropathic Pain.

Alleviating Neuropathic Pain Hypersensitivity by Inhibiting PKMζ in the Anterior Cingulate Cortex

Resveratrol Attenuates Inflammatory Hyperalgesia by Inhibiting Glial Activation in Mice Spinal Cords

Molecular and Behavioral Changes in Nociception in a Novel Rat Model of Chronic Pancreatitis for the Study of Pain

Scoping Review: The Role of Psychedelics in the Management of Chronic Pain

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats

The effect of intrathecal administration TRPA1 antagonists in a rat model of neuropathic pain.

Targeting 5-HT2A receptors and Kv7 channels in PFC to attenuate chronic neuropathic pain in rats using a spared nerve injury model

Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats

Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice

Spinal activation of alpha 7-nicotinic acetylcholine 3 receptor attenuates posttraumatic stress

Alleviation of chronic pain following rat spinal cord compression injury with multimodal actions of huperzine A

Preemptive minocycline decreases allodynia and depressive-like behaviors in a peripheral neuropathy rat model: a preliminary study

Spinal activation of alpha7-nicotinic acetylcholine receptor attenuates posttraumatic stress disorder-related chronic pain via suppression of glial activation

S-Ketamine Pretreatment Alleviates Anxiety-Like Behaviors and Mechanical Allodynia and Blocks the Pro-inflammatory Response in Striatum and Periaqueductal Gray from a Post-traumatic Stress Disorder Model.

Long-Lasting Nociplastic Pain Modulation by Repeated Administration of Sigma-1 Receptor Antagonist BD1063 in Fibromyalgia-like Mouse Models

Intrathecally administered pizotifen alleviates neuropathic and inflammatory pain in mice by enhancing GABAergic inhibition